首页    期刊浏览 2024年11月08日 星期五
登录注册

文章基本信息

  • 标题:Ustekinumab is effective in biological refractory Crohn’s disease patients–regardless of approval study selection criteria
  • 本地全文:下载
  • 作者:Sadik Saman ; Martin Goetz ; Judith Wendler
  • 期刊名称:Intestinal Research
  • 印刷版ISSN:1598-9100
  • 电子版ISSN:2288-1956
  • 出版年度:2019
  • 卷号:17
  • 期号:3
  • 页码:340-348
  • DOI:10.5217/ir.2019.00012
  • 出版社:Korean Association for the Study of Intestinal Diseases
  • 摘要:Background/Aims Ustekinumab is effective in active Crohn’s disease. In a retrospective study, we assessed the clinical outcome in nonresponders to anti-tumor necrosis factor therapy, and/or conventional therapy and/or the α4β7-integrin inhibitor vedolizumab. As approval study populations do not always reflect the average “real world” patient cohort, we assessed weather patients who would not have qualified for approval studies show similar outcomes.
  • 关键词:Crohn disease; Ustekinumab; Biological therapy
国家哲学社会科学文献中心版权所有